CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
2.650
+0.020 (0.76%)
Aug 25, 2026, 1:46 PM EDT - Market open
CervoMed Stock Forecast
CRVO's stock price has decreased by -71.41% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 6 analysts polled by S&P Global, CervoMed stock has a consensus rating of "Strong Buy" and an average price target of $15.4. The average 1-year stock price forecast is 481.13% higher than the current stock price, while the lowest is $7.00 (+164.15%) and the highest is $25 (+843.40%).
Price Target: $15.4 (+481.13%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for CervoMed stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 7 | 7 | 6 | 6 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Buy Maintains $9 → $7 | Buy | Maintains | $9 → $7 | +164.15% | Aug 20, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +843.40% | Aug 12, 2026 |
| JonesTrading | JonesTrading | Buy Reiterates $20 → $12 | Buy | Reiterates | $20 → $12 | +352.83% | Aug 10, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $18 | Buy | Reiterates | $18 | +579.25% | Aug 10, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $21 | Buy | Reiterates | $21 | +692.45% | May 18, 2026 |
Financial Forecast
Revenue This Year
133.33K
from 4.01M
Decreased by -96.67%
Revenue Next Year
833.33K
from 133.33K
Increased by 525.01%
EPS This Year
-2.20
from -2.98
EPS Next Year
-1.48
from -2.20
EPS and Forward PE are based on non-GAAP adjusted numbers.